We found for
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
![Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies](https://www.ohe.org/wp-content/uploads/2023/01/Cancer_WellcomeCollection_landscape.jpg)
A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
![OHE Report_Henderson et al](https://www.ohe.org/wp-content/uploads/2021/11/OHE-Report_Henderson-et-al._Multi-indication-Rare-Diseases-2-01.png)
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
![Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies](https://www.ohe.org/wp-content/uploads/2020/08/Bridge-150x150.png)